Marker Therapeutics, Inc. Profile Avatar - Palmy Investing

Marker Therapeutics, Inc.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indic…

Biotechnology
US, Houston [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of MRKR's Analysis
CIK: 1094038 CUSIP: 57055L107 ISIN: US57055L2060 LEI: - UEI: -
Secondary Listings
MRKR has no secondary listings inside our databases.